title: [The effectiveness of certain magnesium salts in nephrolithiasis caused by the use of sodium oxalate and celecoxib].
abstract: The study was aimed to evaluation the effect of different magnesium salts and their combinations with pyridoxine on a course of calcium-oxalate nephrolithiasis, which was modeled by adding the sodium oxalate (3% of weight of the diet) and selective cyclooxygenase-2 inhibitor celecoxib at a dose 100 mg/kg body weight to a diet for 4 weeks. Starting from the 2nd week of the experiment, the animals had received one of the following compounds: magnesium L-aspartate, magnesium chloride, and their combination with vitamin B6; magnesium sulfate and Magne B6 (magnesium lactate and vitamin B6) as comparators. 28 days after the start of the experiment, disorders progressed in the group receiving only celecoxib and oxalate-rich diet: the urine level of oxalate increased by 171% (p < 0,0001), crystalluria had increased (up to 105 crystals in 10 microml of urinary sediment, p < 0,0001), creatinine clearance decreased by 29%, compared to control (p = 0,087). Increasing calcium/magnesium and oxalate/creatinine ratios in urine by 16 and 189%, respectively, was observed. In the renal parenchyma of animals treated with sodium oxalate and celebrex, calcifications with a volume fraction of 4% were identified, whereas these changes were absent in intact animals. According to the degree of correction ofhyperoxaluria and elimination of calcium oxalate crystals, investigated salts showed similar efficacy, with the exception of magnesium sulfate, which less contributed the compensation of abnormalities in kidney and urinary. According to the data of morphological study, the volume fraction of calcifications was lowest in the groups receiving magnesium L-aspartate and Magne B6.
authors: A A
authors: AA
authors: Spasov
authors: I N
authors: IN
authors: Iezhitsa
authors: M V
authors: MV
authors: Kharitonova
authors: M S
authors: MS
authors: Kravchenko
authors: G L
authors: GL
authors: Snigur
authors: V B
authors: VB
authors: Pisarev
mesh_terms: D000818:Animals; D001224:Aspartic Acid / Q000494:pharmacology; D000068579:Celecoxib; D003404:Creatinine / Q000378:metabolism; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology*; D007668:Kidney / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D019344:Lactic Acid / Q000494:pharmacology; D015636:Magnesium Chloride / Q000494:pharmacology*; D008297:Male; D053040:Nephrolithiasis / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D019815:Oxalic Acid / Q000494:pharmacology*; D011720:Pyrazoles / Q000494:pharmacology*; D051381:Rats; D019163:Reducing Agents / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology*
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D019163:Reducing Agents; D013449:Sulfonamides; D015636:Magnesium Chloride; D001224:Aspartic Acid; D019344:Lactic Acid; D019815:Oxalic Acid; D003404:Creatinine; D000068579:Celecoxib